/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/
OTTAWA, April 1, 2020 /CNW Telbec/ - Tetra
Bio-Pharma Inc. ("Tetra" or the "Corporation")
(TSXV: TBP) (OTCQB: TBPMF) announced today that it has filed a
final short form base shelf prospectus with the securities
commissions in each of the provinces of Canada.
The base shelf prospectus will allow Tetra and certain of its
security holders to qualify the distribution by way of prospectus
of up to $50,000,000 of common
shares, warrants, units, debt securities, subscription receipts, or
any combination thereof, from time to time during the 25-month
period that the shelf prospectus is effective. The specific terms
of any future offering, and the intended use of the net proceeds
resulting from such offering, will be established in a prospectus
supplement to the shelf prospectus, which supplement will be filed
with the applicable Canadian securities regulatory authorities in
connection with any such offering. The nature, size and timing of
any such offerings (if any) will depend, in part, on Tetra's
assessment of its requirements for funding and general market
conditions.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any province, state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
province, state or jurisdiction.
A copy of the final short form base shelf prospectus can be
found on SEDAR at www.sedar.com.
About Tetra Bio-Pharma
Tetra Bio-Pharma
(TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in
cannabinoid-based drug discovery and development with a Health
Canada approved, and FDA reviewed and approved, clinical program
aimed at bringing novel prescription drugs and treatments to
patients and their healthcare providers. The Company has several
subsidiaries engaged in the development of an advanced and growing
pipeline of Bio Pharmaceuticals, Natural Health and Veterinary
Products containing cannabis and other medicinal plant-based
elements. With patients at the core of what we do, Tetra Bio-Pharma
is focused on providing rigorous scientific validation and safety
data required for inclusion into the existing bio pharma industry
by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com or contact
Tetra Bio-Pharma Inc.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Corporation believes, expects or anticipates
will or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Corporation's ability
to control or predict, that may cause the actual results of the
Corporation to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Corporation to obtain sufficient financing to execute the
Corporation's business plan; competition; regulation and
anticipated and unanticipated costs and delays, the success of the
Corporation's research and development strategies, including the
success of this product or any other product, the applicability of
the discoveries made therein, the successful and timely completion
and uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Corporation's public disclosure record on file with the relevant
securities regulatory authorities. Although the Corporation has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Corporation does not undertake an obligation to publicly update
such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Tetra Bio-Pharma Inc.